These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


142 related items for PubMed ID: 12040453

  • 1. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults.
    Rex JH, Anaissie EJ, Boutati E, Estey E, Kantarjian H.
    Leukemia; 2002 Jun; 16(6):1197-9. PubMed ID: 12040453
    [No Abstract] [Full Text] [Related]

  • 2. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia].
    Andrade M A, Puga L B, Guerra C C, Molina E J, Capurro C M.
    Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390
    [Abstract] [Full Text] [Related]

  • 3. Posaconazole prophylaxis in patients with acute myelogenous leukaemia--results from an observational study.
    Egerer G, Geist MJ.
    Mycoses; 2011 Jan; 54 Suppl 1():7-11. PubMed ID: 21126266
    [Abstract] [Full Text] [Related]

  • 4. Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles.
    Dellacasa CM, Busca A, Audisio E, Marmont F, Barbui AM, Falda M, De Rosa FG, Frairia C, Allione B, D'Ardia S, Aydin S, Pecoraro C, Manetta S, Vitolo U.
    J Chemother; 2014 Oct; 26(5):315-20. PubMed ID: 24075616
    [No Abstract] [Full Text] [Related]

  • 5. [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].
    Selvy N, Villiet M, Hansel-Esteller S.
    Pathol Biol (Paris); 2010 Apr; 58(2):123-6. PubMed ID: 19864087
    [Abstract] [Full Text] [Related]

  • 6. Risks and outcome of fungal infection in neutropenic children with hematologic diseases.
    Aytaç S, Yildirim I, Ceyhan M, Cetin M, Tuncer M, Kara A, Cengiz AB, Seçmeer G, Yetgin S.
    Turk J Pediatr; 2010 Apr; 52(2):121-5. PubMed ID: 20560245
    [Abstract] [Full Text] [Related]

  • 7. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
    Lewis G, Hall P, Eisa N, Deremer D, Dobbins R, El-Geneidy M, Jillella A, Ustun C.
    Acta Haematol; 2010 Apr; 124(4):206-13. PubMed ID: 21071929
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
    Cornely OA, Böhme A, Reichert D, Reuter S, Maschmeyer G, Maertens J, Buchheidt D, Paluszewska M, Arenz D, Bethe U, Effelsberg J, Lövenich H, Sieniawski M, Haas A, Einsele H, Eimermacher H, Martino R, Silling G, Hahn M, Wacker S, Ullmann AJ, Karthaus M, Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology.
    J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials.
    Ziakas PD, Kourbeti IS, Voulgarelis M, Mylonakis E.
    Clin Ther; 2010 Dec; 32(14):2316-36. PubMed ID: 21353103
    [Abstract] [Full Text] [Related]

  • 10. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
    Fisher BT, Zaoutis T, Dvorak CC, Nieder M, Zerr D, Wingard JR, Callahan C, Villaluna D, Chen L, Dang H, Esbenshade AJ, Alexander S, Wiley JM, Sung L.
    JAMA; 2019 Nov 05; 322(17):1673-1681. PubMed ID: 31688884
    [Abstract] [Full Text] [Related]

  • 11. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J.
    Clin Infect Dis; 2005 Nov 01; 41(9):1242-50. PubMed ID: 16206097
    [Abstract] [Full Text] [Related]

  • 12. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
    Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U, Wörmann B, Büchner T, Hiddemann W.
    Cancer; 1998 Jul 15; 83(2):291-301. PubMed ID: 9669812
    [Abstract] [Full Text] [Related]

  • 13. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve.
    Portugal RD, Garnica M, Nucci M.
    J Clin Oncol; 2009 Aug 10; 27(23):3849-54. PubMed ID: 19597026
    [Abstract] [Full Text] [Related]

  • 14. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA.
    J Antimicrob Chemother; 2010 Jul 10; 65(7):1466-71. PubMed ID: 20410061
    [Abstract] [Full Text] [Related]

  • 15. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
    Heimann SM, Cornely OA, Vehreschild MJ, Glossmann J, Kochanek M, Kreuzer KA, Hallek M, Vehreschild JJ.
    Mycoses; 2014 Feb 10; 57(2):90-7. PubMed ID: 23790060
    [Abstract] [Full Text] [Related]

  • 16. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA.
    J Infect; 2007 Nov 10; 55(5):445-9. PubMed ID: 17822770
    [Abstract] [Full Text] [Related]

  • 17. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S.
    Cancer; 2002 Jun 15; 94(12):3230-46. PubMed ID: 12115356
    [Abstract] [Full Text] [Related]

  • 18. Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favourable outcome during induction chemotherapy for acute leukaemias.
    Khalafallah A, Maiwald M, Hannan T, Abell S, Staker J, Supperamohan A.
    Intern Med J; 2012 Feb 15; 42(2):131-6. PubMed ID: 22151972
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    AbuTarif MA, Krishna G, Statkevich P.
    Curr Med Res Opin; 2010 Feb 15; 26(2):397-405. PubMed ID: 20001450
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation.
    Gupta S, Almyroudis NG, Battiwalla M, Bambach BJ, McCarthy PL, Proefrock AD, Ball D, Paplham P, Varma A, Kwon-Chung J, Segal BH.
    Transpl Infect Dis; 2007 Jun 15; 9(2):156-60. PubMed ID: 17462004
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.